Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma
Eligible participants must have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody. This study as two experimental arms. Experimental Arm A is a dose-escalation and expansion study of XmAb24306 + Cevostamab. Participants will receive escalating doses of XmAb24306 (administered intravenously on a 28-day cycle) plus a fixed dose regimen for cevostamab (administered intravenously on a 28-day cycle) up to the maximum tolerated dose. After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled. Experimental Arm B is a single-agent cevostamab expansion arm. Participants will receive cevostamab alone (administered intravenously on a 28-day cycle). In both arms, tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.